InnoCare Pharma Ltd
HKEX:9969
Relative Value
The Relative Value of one InnoCare Pharma Ltd stock under the Base Case scenario is 12.08 HKD. Compared to the current market price of 5.08 HKD, InnoCare Pharma Ltd is Undervalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
InnoCare Pharma Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CN |
InnoCare Pharma Ltd
HKEX:9969
|
9B HKD | 13.2 | -9.3 | 1 | 1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
288.1B USD | 5.3 | 59.8 | 13 | 19.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
104.8B USD | 10.7 | 29.1 | 23.2 | 24.3 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 169.1 | 6.8 | 8.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.2 | 14 | 17.5 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |